BICYCLE THERAPEUTICS PLC 8-K

What Happened
Bicycle Therapeutics plc announced the results of its annual general meeting held June 17, 2026. About 49,696,908 ordinary shares were represented (≈98.64% of issued and outstanding shares). All nine proposals on the agenda were approved on a poll, including the re-election of two directors, advisory approval of executive compensation, ratification and re-appointment of PricewaterhouseCoopers LLP as auditors, and approval of the directors’ remuneration policy.

Key Details

• Total shares represented: 49,696,908 (≈98.64% of shares outstanding). Proxy appointments giving the Chairman discretion and discretionary ADS proxies were included in the results.
• Proposal 1 — Re-election of Felix Baker: For 46,171,302; Against 3,364,113; Withheld 161,493.
• Proposal 2 — Re-election of Hervé Hoppenot: For 49,284,459; Against 250,669; Withheld 161,780.
• Proposal 3 — Advisory approval of named executive officers’ compensation (say-on-pay): For 48,748,743; Against 785,032; Withheld 163,133.
• Proposal 4/5 — Ratification and re-appointment of PwC as registered public accounting firm and U.K. statutory auditors: For 49,445,128 / 49,441,337 respectively.
• Proposal 9 — Approval of directors’ remuneration policy (effective immediately after AGM): For 48,238,031; Against 1,293,722; Withheld 165,155.

Why It Matters
These results confirm board continuity and governance arrangements that affect company oversight and executive pay. Ratifying PwC maintains continuity in external audit coverage. The advisory approval of executive compensation and the binding approval of the directors’ remuneration policy provide shareholders’ endorsement of Bicycle Therapeutics’ pay framework and governance approach. The high turnout (≈98.6%) indicates strong shareholder engagement in these governance decisions.